Radioactive iodine for differentiated thyroid carcinoma
RAI in DTC is evolving towards a risk-adapted model. Escalating evidence indicates that RAI may be safely withheld in a large proportion of low-risk DTC. Optimal management of intermediate-risk DTC remains controversial, due to heterogeneity in clinical and pathological characteristics and conflicting data over survival advantage. Well designed studies incorporating molecular genotype may be key in identifying those most likely to benefit from RAI and in elucidating mechanisms of RAI-resistance.
Authors
- Saumya Sunny (ORCID: https://orcid.org/0000-0001-9233-8217)
- David Colville
- Kathryn Graham (ORCID: https://orcid.org/0000-0001-6725-1021)
- Julie Hephzibah (ORCID: https://orcid.org/0000-0002-9917-3926)
Institutions
- Christian Medical College, Vellore (IN)
- Beatson West of Scotland Cancer Centre (GB)
- Glasgow Royal Infirmary (GB)
- Christian Medical College (IN)
Publication Details
- Journal
- Current Opinion in Endocrinology Diabetes and Obesity
- Published
- 2025-10-03
- DOI
- https://doi.org/10.1097/med.0000000000000932
- Citations
- 1
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.29